Screener
Repligen RGEN R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Repligen in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Repligen’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323773
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenue | 204,128 | 182,366 | 398,383 | 351,538 |
| Costs and operating expenses: | ||||
| Cost of goods sold | 94,091 | 89,371 | 180,062 | 167,172 |
| Research and development | 14,417 | 13,970 | 28,875 | 26,084 |
| Selling, general and administrative | 76,618 | 70,906 | 153,154 | 141,612 |
| Restructuring activities and other charges | 2,718 | 2,162 | 4,214 | 4,135 |
| Change in fair value of contingent consideration | 2,308 | (7,939) | 2,162 | (7,939) |
| Total costs and operating expenses | 190,152 | 168,470 | 368,467 | 331,064 |
ITEM 1. Financial Statements
FAQ
- What is Repligen's R&D?
- Repligen (RGEN) reported R&D of $14.42M in Q2 2026.
- How has Repligen's R&D changed year-over-year?
- Repligen's R&D increased by 3.3% year-over-year, from $13.96M to $14.42M.
- What is the long-term trend for Repligen's R&D?
- Over 2 years (2021 to 2023), Repligen's R&D has grown at a 11.6% compound annual growth rate (CAGR), from $34.27M to $42.72M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Repligen's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude